Novartis Says Kisqali NATALEE Analysis Reinforces Consistent Reduction In Risk Of Recurrence Across Key Subgroups Of Patients With Early Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Novartis has announced that an analysis of Kisqali NATALEE reinforces consistent reduction in the risk of recurrence across key subgroups of patients with early breast cancer.

October 20, 2023 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' Kisqali NATALEE analysis could potentially boost the company's reputation and sales in the oncology sector.
The positive analysis of Kisqali NATALEE by Novartis could potentially increase the company's sales and reputation in the oncology sector. This is because the analysis shows a consistent reduction in the risk of recurrence in early breast cancer patients, which could lead to increased usage of the drug by healthcare providers. This could in turn lead to increased sales for Novartis.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100